IBRX280121P00005500
IBRX Jan 21 2028 5.50 Put
optionOPRA
EODOct 19, 2026
1.18USD-25.316%(-0.40)10Vol3,931OI
Loading…
Underlying
Underlying Price
$8.68
Type
Put
Strike
5.5
Expiration
Jan 21, 2028
DTE
458d
Moneyness
OTM
Intrinsic
$0.00
IBRX 5.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.35 | +16.67% | 1,121 | 34,106 |
| Jan 21, 2028 | 458d | $1.18 | -25.32% | 10 | 3,931 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2.5 P | $0.23 | +0.00% | 2 | 165 | OTM |
| 3 P | $0.35 | +6.06% | 4 | 207 | OTM |
| 3.5 P | $1.54 | +180.00% | 2 | 12 | OTM |
| 4 P | $3.33 | +152.27% | 3 | 24 | OTM |
| 4.5 P | $1.35 | -38.07% | 234 | 250 | OTM |
| 5 P | $0.98 | +8.89% | 1 | 974 | OTM |
| 5.5 P | $1.18 | -25.32% | 10 | 3,931 | OTM |
| 7.5 P | $1.95 | -9.30% | 125 | 9,702 | OTM |
| 10 P | $3.99 | +14.00% | 1 | 3,805 | ITM |
| 12 P | $4.98 | -4.23% | 10 | 42 | ITM |
| 15 P | $7.25 | -14.71% | 1 | 676 | ITM |
| 17 P | $8.75 | -1.02% | 5 | 8 | ITM |
| 20 P | $14.10 | +6.82% | 2 | 37 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.